Amendments

In accordance with 37 CFR §1.121, please amend the above-identified application as set forth below.

Amendments to the Claims: The following listing of claims will replace all prior versions, and listings, of claims in the application:

1-15. (Cancelled)

16. (Previously presented)A method of treating migraine, comprising the steps of:

reconstituting a pharmaceutically effective amount of Botulinum toxin type A with saline;

mixing the reconstituted Botulinum toxin type A with a base including a pluronic lecithin organogel; and

transdermally applying the mixture of reconstituted Botulinum toxin type A and base to an affected area of a human exhibiting symptoms of migraine.

17-21. (Canceled).

22. (Currently amended) ~~The method of inhibiting the release of neurotransmitters in trigeminal neurons as set forth in claim 21,~~

A method of inhibiting the release of neurotransmitters in trigeminal neurons, comprising the steps of:

preparing a topical solution in which Botulinum toxin type A is the active ingredient, wherein the step of preparing a topical solution further comprises the steps of:

reconstituting a pharmaceutically effective amount of Botulinum toxin type A with saline; and

mixing the reconstituted Botulinum toxin type A with a suitable base, wherein the suitable base includes a pluronic lecithin organogel;

transdermally applying a pharmaceutically effective amount of Botulinum toxin type A to an affected area of a human exhibiting symptoms of migraine, wherein the neuropeptide inhibited is calcitonin gene-related peptide.

23-24. (Canceled).

25. (New) A topical pharmaceutical composition comprising:

a pharmaceutically effective amount of Botulinum toxin type A reconstituted with saline; and

a suitable base for transdermal delivery of said Botulinum toxin type A wherein said base includes a pluronic lecithin organogel.